<table sstyle="width:80%" align="center" border=1>
<tr>
<th>mv</th>
<th>dw</th>
<th>HMMCrowd</th>
</tr>
<tr>
<td width=33%>
[35, 57] patients with epithelial ovarian carcinoma that recurred after or didn't respond to first-line, platinum-based chemotherapy.<br>[61, 67] Patients with measurable and assessable disease<br>[117, 119] 474 patients<br></td>
<td width=33%>
[35, 57] patients with epithelial ovarian carcinoma that recurred after or didn't respond to first-line, platinum-based chemotherapy.<br>[61, 67] Patients with measurable and assessable disease<br>[114, 121] A total of 474 patients were treated<br></td>
<td width=33%>
[35, 58] patients with epithelial ovarian carcinoma that recurred after or didn't respond to first-line, platinum-based chemotherapy.
<br>[61, 67] Patients with measurable and assessable disease<br>[114, 129] A total of 474 patients were treated (239 PLD and 235 topotecan).<br></td>
</tr>
